Document Detail


T-cell biology in immunotherapy.
MedLine Citation:
PMID:  24565594     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: This review discusses the current state of immunotherapy and how the CD4 T-cell response is pivotal in altering the allergic response.
DATA SOURCES: PubMed literature review.
STUDY SELECTIONS: Articles pertaining to subcutaneous, sublingual, and oral immunotherapies, with specific emphasis on those describing the T-cell response.
RESULTS: Although many drugs are available that help ameliorate allergic symptoms, the only intervention that has proved to provide long-term benefit and modulation of disease is immunotherapy. Many routes of immunotherapy are being pursued, including subcutaneous, sublingual, and oral immunotherapies; however, subcutaneous immunotherapy has the historical record of leading to immune changes that alter the immune response at subsequent allergen exposure. These changes are mediated by the induction of peripherally derived T-regulatory cells and appear to occur only after high-dose therapy for 3 to 5 years. Newer methods of sublingual and oral immunotherapies are currently being investigated, but their efficacy is not yet on par with subcutaneous immunotherapy.
CONCLUSION: The primary cells ultimately responsible for successful immunomodulation are CD4 T cells, specifically peripherally derived T-regulatory cells.
Authors:
John W Steinke; Monica G Lawrence
Related Documents :
24756774 - Prospects for engineering neurons from local neocortical cell populations as cell-media...
23345394 - The shc family protein adaptor, rai, acts as a negative regulator of th17 and th1 cell ...
23800654 - Fine tuning a well-oiled machine: influence of nk1.1 and nkg2d on nkt cell development ...
24629634 - Programmed death-1 receptor suppresses γ-ifn producing nkt cells in human tuberculosis.
19155484 - Tim-1 signaling substitutes for conventional signal 1 and requires costimulation to ind...
9353034 - Direct interactions of human natural killer cells with cryptococcus neoformans inhibit ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2014-01-14
Journal Detail:
Title:  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology     Volume:  112     ISSN:  1534-4436     ISO Abbreviation:  Ann. Allergy Asthma Immunol.     Publication Date:  2014 Mar 
Date Detail:
Created Date:  2014-02-25     Completed Date:  2014-04-22     Revised Date:  2014-05-07    
Medline Journal Info:
Nlm Unique ID:  9503580     Medline TA:  Ann Allergy Asthma Immunol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  195-9     Citation Subset:  IM    
Copyright Information:
Copyright © 2014 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antigens, CD4 / metabolism
Desensitization, Immunologic / methods
Humans
Hypersensitivity / immunology,  therapy*
Immunotherapy / methods*
Injections, Subcutaneous
Interleukin-10 / immunology
Interleukin-2 Receptor alpha Subunit / metabolism
T-Lymphocytes, Regulatory / immunology*
Transforming Growth Factor beta / immunology
Grant Support
ID/Acronym/Agency:
R01 AI057438/AI/NIAID NIH HHS
Chemical
Reg. No./Substance:
0/Antigens, CD4; 0/Interleukin-2 Receptor alpha Subunit; 0/Transforming Growth Factor beta; 130068-27-8/Interleukin-10

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Remote ischemic preconditioning and endothelial function in patients with acute myocardial infarctio...
Next Document:  Initial characteristics and outcome of hospitalized patients with amiodarone pulmonary toxicity.